Form 4: Oragenics Director Awarded 125,000 Stock Options

Oragenics Inc. Director Robert C. Koski received an award of 125,000 stock options with an exercise price of $0.93, vesting immediately.

Summary

• Robert C. Koski, a Director of Oragenics Inc. (OGEN), was granted 125,000 non-employee director options to purchase shares of the company's Common Stock.
• The transaction date for this award was December 11, 2025.
• The exercise price for these options is $0.93 per share, which was the company's closing price on the date of grant.
• The options vest immediately upon grant and have an expiration date of December 11, 2035.
• This award was made under the Company's 2021 Equity Incentive Plan, as amended, as part of the non-employee director compensation program.
• Following this transaction, Robert C. Koski beneficially owns 125,000 derivative securities directly.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates director alignment with shareholder interests through equity compensation, a standard corporate governance practice.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, encouraging long-term value creation.
• The immediate vesting of options provides immediate equity exposure and incentive for the director.

Negatives

• No specific negative aspects are directly reported in this Form 4 filing, which primarily details an insider transaction.

Risks

• The exercise of these options in the future could lead to a slight dilution of existing shareholders' equity, depending on the number of outstanding shares at that time.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance, but rather reports a past insider transaction.

Industry Context

The granting of stock options to non-employee directors is a common practice across various industries, particularly in biotechnology and pharmaceutical sectors like Oragenics, to attract and retain qualified board members and align their interests with long-term shareholder value.

Comparison to Industry Standards

• Equity compensation for non-employee directors, such as stock options, is a standard practice in publicly traded companies, including those in the biotechnology sector, to incentivize performance and align interests.
• The immediate vesting of director options is also common, reflecting compensation for ongoing board service rather than performance milestones.

Corporate Governance

Related Party Transactions

• The transaction involves an award of stock options to a director, which is a form of compensation and an insider transaction.

Stakeholder Impact

• Shareholders: Potential for increased alignment of director interests with long-term shareholder value. Minor potential for dilution if options are exercised.
• Employees: No direct impact mentioned for general employees.

Next Steps

• Robert C. Koski may choose to exercise these options at any time between the vesting date (December 11, 2025) and the expiration date (December 11, 2035), assuming the stock price is above the exercise price.

Key Dates

Keywords

Oragenics Inc., OGEN, Stock Options, Director Compensation, Insider Transaction, Equity Incentive Plan, SEC Form 4